AJP - Heart AJP: Advances in Physiology Education
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 284: H635-H643, 2003. First published October 10, 2002; doi:10.1152/ajpheart.00986.2001
0363-6135/03 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
284/2/H635    most recent
00986.2001v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (20)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Castoldi, G.
Right arrow Articles by Stella, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Castoldi, G.
Right arrow Articles by Stella, A.
Vol. 284, Issue 2, H635-H643, February 2003

ANG II increases TIMP-1 expression in rat aortic smooth muscle cells in vivo

Giovanna Castoldi1,*, Cira R. T. di Gioia2,*, Federico Pieruzzi1, Cristina D'Orlando1, Willy M. M. van de Greef3, Giuseppe Busca1, Giovanni Sperti3, and Andrea Stella1

1 Unitá Didattico Assistenziale Nefrocardiovascolare, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Università degli Studi di Milano-Bicocca 20052, Monza and Centro di Fisiologia Clinica e Ipertensione, Ospedale Maggiore, Instituto di Ricovero e Cura a Carattere Scienti, 20100 Milan; 2 Dipartimento di Medicina Sperimentale e Patologia, Istituto di Anatomia Patologica, Università La Sapienza, 00161 Rome; and 3 Istituto di Cardiologia, Università Cattolica, 00168 Rome, Italy


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are involved in tissue remodeling processes. TIMP-1 is the main native inhibitor of MMPs and it contributes to the development of tissue fibrosis. It is known that ANG II plays a fundamental role in vascular remodeling. In this study, we investigated whether ANG II modulates TIMP-1 expression in rat aortic smooth muscle cells. In vitro, ANG II induces TIMP-1 mRNA expression in a dose-dependent manner. The maximal increase in TIMP-1 expression was present after 3 h of ANG II stimulation. The ANG II increase in TIMP-1 expression was mediated by the ANG type 1 receptors because it was blocked by losartan. The increase in TIMP-1 expression was present after the first ANG II treatment, whereas repeated treatments (3 and 5 times) did not modify TIMP-1 expression. In vivo, exogenous ANG II was administered to Sprague-Dawley rats (200 ng · kg-1 · min-1 sc) for 6 and 25 days. Control rats received physiological saline. After treatment, systolic blood pressure was significantly higher (P < 0.01), whereas plasma renin activity was suppressed (P < 0.01), in ANG II-treated rats. ANG II increased TIMP-1 expression in the aorta of ANG II-treated rats both at the mRNA (P < 0.05) and protein levels as evaluated by Western blotting (P < 0.05) and/or immunohistochemistry. Neither histological modifications at the vascular wall nor differences in collagen content in the tunica media were present in both the ANG II- and saline-treated groups. Our data demonstrate that ANG II increases TIMP-1 expression in rat aortic smooth muscle cells. In vivo, both short- and long-term chronic ANG II treatments increase TIMP-1 expression in the rat aorta. TIMP-1 induction by ANG II in aortic smooth muscle cells occurs in the absence of histological changes at the vascular wall.

collagen; experimental hypertension; vessels


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

VASCULAR SMOOTH MUSCLE CELLS (VSMC) are involved in the pathogenesis of atherosclerosis, restenosis, and hypertension. In vivo, VSMC are surrounded by extracellular matrix proteins; in the normal vascular wall, they remain in a contractile state, whereas in response to injury they can assume a synthetic phenotype. VSMC may synthetize collagen, matrix proteins, and enzymes involved in extracellular matrix degradation, such as plasminogen activators and metalloproteinases and their inhibitors (19, 22, 26).

ANG II has multiple effects on VSMC. It increases matrix protein synthesis and has profibrotic effects (14, 15). In addition, in experimental models (9, 23), ANG II may modulate the expression of the matrix metalloproteinases (MMPs), the main extracellular matrix degradation enzymes, whose activity is in turn tightly regulated by endogenous tissue inhibitors.

To date, little is known about the effects of ANG II on the endogenous tissue inhibitors of the MMP system (TIMPs) that is considered one of the major factors involved in tissue remodeling and in the development of tissue fibrosis (1, 28). Four types of TIMPs have been identified (2, 12). Among these, TIMP-1 is produced by different cell types, including most types of connective tissue cells and those involved in the inflammatory processes (18). It has been shown that TIMP-1 inhibits with different affinity all members of the collagenases, stromelysins, and gelatinases (8). In the tunica media, the constitutive expression of TIMP-1 plays an important role in vessel wall homeostasis (21). Overexpression of TIMP-1 retards vascular cell migration in the injured rat carotid artery (10). Besides the inhibition on matrix metalloproteinases, TIMP-1 has also some MMP inhibitory-independent effects. In some cell types, as erythroid progenitors (4), TIMP-1 shows growth factor-like effects. In addition, a role of TIMP-1 in modulation of apoptosis processes in B cells (13) and mesangial cells (16) has been recently described.

It has been demonstrated that ANG II increases TIMP-1 expression in rat heart endothelial cells in culture (6), whereas the effect in vivo of ANG II on TIMP-1 expression in VSMC, which is the major source of extracellular matrix components implicated in the vascular remodeling process, is unknown.

Our experiments were done to verify in vitro whether ANG II modulates TIMP-1 mRNA expression in rat aortic smooth muscle cells and to investigate in vivo the effect of chronic ANG II administration on TIMP-1 expression in rat aortic smooth muscle cells in conscious rats.


    METHODS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Cell Cultures

Rat aortic smooth muscle cells were isolated from 10- to 12-wk-old male Sprague-Dawley rats by enzymatic dispersion. Cells were cultured in Dulbecco's modified Eagle's medium (Bio-Whittaker; Verviers, Belgium) supplemented with 10% fetal calf serum, 4 mM glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin (GIBCO; Paisley, UK). Cells (passages 5-15) were cultured at 37°C in an incubator in a 5% CO2-humidified atmosphere until confluence, rinsed twice with serum-free (SF) medium, and incubated in SF medium for 48 h. For time-course experiments at time 0, ANG II (5 × 10-8 M) or the same volume of vehicle was added to parallel cultures and subsequently collected after 1, 3, 8, and 24 h. Because the time-course experiments demonstrated that the ANG II-induced TIMP-1 mRNA signal was maximal at 3 h, the dose-response experiments were performed in VSMC after 3 h of treatment with the use of the following ANG II concentrations (in M): 5 × 10-10, 1 × 10-9, 5 × 10-9, 1 × 10-8, and 2 × 10-7. The same volume of vehicle was added to control cultures. In ANG type 1 (AT1) receptor blocker experiments, losartan (1 × 10-6 M) was added to ANG II (5 × 10-8 M) at the same time, and the cells were incubated for 3 h. To evaluate the effect of repeated ANG II treatments on TIMP-1 expression, cells were treated one, three, and five consecutive times with ANG II (5 × 10-8 M) for 4 h of treatment.

In Vivo Experiments

The experiments were conducted in accordance with the European Convention on Animal Protection and Guidelines on Research Animal Use.

The experiments were performed in 49 conscious male 12-wk-old Sprague-Dawley rats [200-250 g body wt (BW)]. Animals were individually housed in metabolic cages in a temperature-controlled room with a 12:12-h light-dark cycle for the whole experimental periods and allowed to acclimate to the metabolic cages and the experimental procedures. Rats had free access to a standard rat chow and tap water. Systolic blood pressure (SBP, mmHg), heart rate (HR, beats/min), and BW (g) were measured three times a week by the same investigator who was unaware of the specific treatment. SBP and HR were assessed by the tail-cuff method (average of 6 recordings).

To evaluate the effect of the exogenous administration of ANG II, rats were subcutaneously implanted with osmotic minipumps under pentobarbital sodium anesthesia (40 mg/kg ip) to receive either ANG II at the dose of 200 ng · kg-1 · min-1 (treated groups) or physiological saline (control groups).

One group of 23 rats (n = 11, ANG II treated; n = 12, saline treated) underwent this protocol, and osmotic minipumps (Alzet 2001; Alzet, Palo Alto, CA) delivered ANG II or physiological saline for 6 days. At the end of this period, the rats were euthanized.

Another group of 12 rats (n = 6, ANG II treated; n = 6, saline treated) underwent the same protocol. The osmotic minipumps (Alzet 2001) delivered ANG II or saline for 6 days, but the animals were euthanized 3 wk after the ANG II withdrawal.

To evaluate the effect of longer ANG II infusion, a group of 14 rats (n = 8, ANG II treated; n = 6, saline treated) were subcutaneously implanted with osmotic minipumps (Alzet 2004) to receive ANG II or physiological saline for 25 days. The rats were euthanized at the end of this period.

At the end of the experimental periods, all rats were decapitated and trunk blood was collected to measure plasma renin activity (PRA; AI ng · ml-1 · h-1) by radioimmunoassay. Aortas were immediately excised. For gene and protein expression studies, the media were separated from the adventitia and endothelium, snap-frozen in liquid nitrogen, and stored at -80°C. Aortic TIMP-1 mRNA expression was evaluated by Northern blot analysis and the TIMP-1 protein level was evaluated by Western blotting and/or immunohistochemistry. An aortic ring was fixed with 10% formalin for histological and morphometric analysis.

For immunohistochemical study, an aortic ring was put in a cryomold with OCT compound (Tissue-Tek, Sakura; Zoeterwoude, The Netherlands). The rings were snap-frozen first in isopentane that was previously chilled in liquid nitrogen and again in liquid nitrogen and stored at -80°C until analysis.

Total RNA Extraction and Northern Blot Analysis

Total RNA was extracted from cell cultures and from each aorta according to the guanidium-thiocyanate method used by Chomczynski and Sacchi (5). RNA was quantified on a spectrophotometer determining absorbance at 260 nm, and its integrity was confirmed on an agarose gel stained with ethidium bromide. For Northern blot analyses, 20 µg of RNA were loaded on formaldehyde-agarose (1%) gel, separated by electrophoresis (20), and vacuum blotted (Vacugene, Pharmacia; Uppsala, Sweden) onto a nylon membrane (GeneBind 45, Pharmacia). Blots were hybridized with 32P-labeled rat TIMP-1 cDNA probe (kind gift from Dr. L. Schaefer, University of Muenster, Muenster, Germany) in 0.5 M sodium phosphate and 7% SDS at 60°C and washed twice at 60°C in 2× sodium chloride/sodium citrate and 1% SDS. The same blots were hybridized with a rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA probe.

Blots were exposed to an Instant Imager (Canberra Packard Electronic Autoradiography Instrument) for direct acquisition of data. TIMP-1 expression was normalized to the housekeeping GAPDH gene expression and was reported in arbitrary units (au).

Protein Extraction and Western Analysis

Total proteins were extracted from aortic tissues and homogenized in the presence of EDTA and protease inhibitors (10 mg/ml aprotinine, 10 mg/ml leupeptin, and 1 mg/ml antipain). Protein samples were then separated by 12% SDS-PAGE and transferred onto Hybond-ECL membranes (Amersham). These were saturated with 5% nonfat milk in PBS and 0.1% Tween 20 for 1 h at room temperature and then incubated with a mouse anti-human TIMP-1 monoclonal antibody (dilution 1:300) (Chemicon; Temecula, CA) in the same solution for 2 h. The membranes were rinsed in PBS containing 0.1% Tween 20 and incubated for 1 h in the milk buffer with a peroxidase-coupled sheep anti-mouse IgG (dilution 1:3,000) (Amersham). Immunoreaction signals were visualized with enhanced chemiluminescence (ECL-PLUS, Amersham). alpha -Actin (dilution 1:2,000) (rabbit alpha -actin antibody, Sigma) was used to normalize the immunoreactivity of TIMP-1 in each sample. Densitometric analysis of signals was performed with an Imaging Densitometer (Bio-Rad). Data are expressed (in au) as the TIMP-1-to-alpha -actin ratio.

Histological, Morphometric, and Immunohistochemical Analysis

For histomorphology, aortic samples were fixed with 10% neutral-buffered formalin and subsequently processed and embedded in paraffin wax. Aortic histological sections (5 µm thick) were cut, stained with routine hematoxylin and eosin stain, and studied with light microscopy (Leica).

Collagen deposition in the tunica media was quantified microscopically using a computerized imaging analysis system (IAS 2000, Delta Sistemi; Rome, Italy) from images taken at ×40 magnification (Leica Light Microscopy) by paraffin-embedded aortic sections stained with Sirius red. Collagen deposition in the tunica media was calculated as follows: area of medial collagen content/area of tunica media, and the value was expressed as a percentage. For immunohistochemistry, aortic samples in OCT compound were snap-frozen in isopentane previously chilled in liquid nitrogen and then in liquid nitrogen. The specimens were stored at -80°C until analysis. Four-micrometer-thick sections were treated with 3% hydrogen peroxide for 20 min and then incubated for 30 min at room temperature with a mouse anti-human TIMP-1 monoclonal antibody (dilution 1:50) (Chemicon). The avidin-biotin peroxidase complex was used to label the primary antibody. The reaction product was detected using 3,3-diaminobenzidine. Control experiments were accomplished by omitting the primary antibody.

Statistical Analysis

Data are presented as means ± SE. Data from the cell experiments were assessed with the use of factorial analysis of variance, followed by the Fisher's protected least-significant difference procedure for post hoc comparisons. Differences between ANG II- and saline-treated groups for SBP, HR, BW, PRA, TIMP-1 mRNA and protein expression, and collagen content in the tunica media were analyzed by unpaired Student's t-test. Differences between means were considered significant at P < 0.05.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

In Vitro Experiments

In quiescent VSMC, ANG II (5 × 10-8 M) induced a time-dependent increase in TIMP-1 mRNA expression. A significant increase in the TIMP-1 mRNA signal compared with the unstimulated control cultures was present at 1 h (P < 0.05, n = 4), maximal at 3 h (P < 0.01, n = 4), remained over the control SF values at 8 h, and returned to control SF values at 24 h (Fig. 1A).


View larger version (24K):
[in this window]
[in a new window]
  		Fig. 1.   A: time course of ANG II-induced increase in tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) mRNA expression [mRNA TIMP-1/GAPDH, in arbitrary units (au)] in cultured rat aortic smooth muscle cells. Bar graphs indicate the means ± SE calculated on four separate experiments after quantification of the Northern blot signal. Inset: example of Northern blot showing ANG II-induced (5 × 10-8 M) TIMP-1 mRNA expression at 1, 3, 8, and 24 h and the corresponding serum-free (SF) conditions. *P < 0.05 vs. SF. B: dose-response relationship of the ANG II-induced increase in TIMP-1 mRNA expression (mRNA TIMP-1/GAPDH, au) in cultured rat aortic smooth muscle cells. Inset: example of Northern blot showing the increase in TIMP-1 mRNA expression after a 3-h treatment with increasing doses of ANG II in cultured rat aortic smooth muscle cells. Data are means ± SE calculated on three separate experiments. *P < 0.05 vs. SF.

ANG II induced a dose-dependent increase in TIMP-1 mRNA expression (Fig. 1B), with a maximal effect at a concentration of 5 × 10-9 M (P < 0.05, n = 3).

The block of AT1 receptors with losartan at a concentration of 1 × 10-6 M abolished the ANG II-induced increase in TIMP-1 mRNA expression (P < 0.01, n = 3) (Fig. 2A).


View larger version (28K):
[in this window]
[in a new window]
  		Fig. 2.   A: effect of the ANG type 1 (AT1) receptor blocker losartan (Los) on ANG II-induced increase in TIMP-1 mRNA expression (TIMP-1/GAPDH mRNA, au). Bar graphs indicate the mean ± SE calculated on three separate experiments after the quantification of the Northern signal. Inset: example of Northern blot showing the effect of the AT1 receptor blocker losartan, on ANG II-induced TIMP-1 mRNA increase after a 3-h treatment in cultured rat aortic smooth muscle cells. *P < 0.01 vs. SF; dagger P < 0.01 vs. ANG II. B: effect of ANG II in cultured rat aortic smooth muscle cells after 1, 3, and 5 repeated treatments on TIMP-1 mRNA expression (TIMP-1/GAPDH mRNA, au). Bar graphs indicate the means ± SE calculated on three separate experiments after the quantification of the Northern signal. Inset: example of Northern blot showing the effect of the ANG II after one, three, and five repeated treatments in cultured rat aortic smooth muscle cells. *P < 0.01 vs. SF.

Repeated treatments to the cells with ANG II did not induce TIMP-1 mRNA expression. In fact, ANG II treatment determined an increase in TIMP-1 mRNA expression only after the first single dose (P < 0.05, n = 3) but not after three and five repeated treatments (Fig. 2B).

In Vivo Experiments

Effects of chronic short-term ANG II infusion. Figure 3 shows the in vivo effects of chronic short-term ANG II administration on SBP, PRA, and TIMP-1 expression. After 6 days of treatment, SBP was significantly higher in the ANG II-treated rats compared with the corresponding control animals. PRA in ANG II-treated animals for 6 days was significantly and markedly lower than PRA of saline-treated rats, indicating that ANG II administration, by increasing the circulating level of ANG II, was effective in suppressing renin release. TIMP-1 mRNA expression resulted significantly higher in ANG II-treated rats than in saline-treated rats. The increase in TIMP-1 mRNA expression was accompanied by a significant increase in the TIMP-1 protein level (Fig. 3B), indicating that in the aortic smooth muscle cells the ANG II induction in TIMP-1 mRNA caused an increase in its transduction into the protein.


View larger version (26K):
[in this window]
[in a new window]
  		Fig. 3.   Effects of ANG II administration for 6 days in rats. A: systolic blood pressure (SBP; mmHg) and plasma renin activity (PRA; ANG I ng · ml-1 · h-1) in saline (n = 12)- and ANG II-treated rats (n = 11). *P < 0.01. B: TIMP-1 mRNA expression (mRNA TIMP-1/GAPDH, au) in saline (n = 8)- and ANG II-treated rats (n = 7). Inset: example of Northern blot showing TIMP-1 mRNA expression in both groups of rats. TIMP-1 protein level (TIMP-1/alpha -actin, au) in saline (n = 4)- and ANG II-treated rats (n = 4). Inset: example of Western blot showing TIMP-1 protein expression in both groups of rats. Data are means ± SE. *P < 0.01 for mRNA and P < 0.05 for protein expression.

At the end of the treatment period, BW and HR in the saline-treated group were higher than in ANG II-treated group (302.3 ± 4.4 vs. 283.7 ± 4.0 g, P < 0.01; 412.9 ± 9.2 vs. 380.7 ± 14.1 beats/min, P = 0.06, respectively).

The increase in TIMP-1 protein expression in aortas of ANG II-treated rats was also demonstrated by immunohistochemistry (Fig. 4A). In ANG II-treated rats, aortic smooth muscle cells showed a stronger immunostaining of TIMP-1 than aortic smooth muscle cells of saline-treated rats. As shown in Fig. 4B, the administration of ANG II caused no histological modification at the vascular wall. No differences in collagen content (Fig. 4C), calculated as the fibrosis percentage in the tunica media, were present between saline- and ANG II-treated rats (%fibrosis: 13.1 ± 1.4 vs. 13.4 ± 1.2, P = 0.88).


View larger version (103K):
[in this window]
[in a new window]
  		Fig. 4.   A: representative photomicrographs (×10) of aorta immunostaining for TIMP-1 antigen in aorta obtained from saline (n = 3)- and ANG II (n = 3)-treated rats for 6 days. Aortic smooth muscle cells of ANG II-treated rat show a stronger immunostaining of TIMP-1 than aortic smooth muscle cells of saline-treated rat. B: representative histological section of aorta from saline (n = 8)- and ANG II-treated rats (n = 10). No histological changes are evident between the aortas of the two groups (hematoxylin and eosin, ×10). C: representative histological section of aorta obtained from saline (n = 8)- and ANG II (n = 10) treated rats, stained with Sirius red for morphometric analysis (×10). Collagen stains with a red color. No differences in collagen content are present in the aortic media between the two groups.

Effects of ANG II infusion withdrawal. Figure 5 shows the results obtained 3 wk after the withdrawal of ANG II administration (6 days) on SBP, PRA, and TIMP-1 mRNA expression. As expected, after 6 days of ANG II infusion, the increase in blood pressure was similar to that observed in both ANG II groups treated for 6 and 25 days (data not shown); then blood pressure, after ANG II withdrawal, progressively decreased to values similar to the corresponding saline-treated group. As shown in Fig. 5, no differences in SBP, PRA, and TIMP-1 mRNA expression were observed after 3 wk of ANG II withdrawal in the rats previously treated with ANG II compared with the corresponding control animals.


View larger version (10K):
[in this window]
[in a new window]
  		Fig. 5.   Effects obtained 3 wk after the withdrawal of ANG II administration (6 days) in rats. A: SBP (mmHg); B: PRA (ANG I ng · ml-1 · h-1); C: TIMP-1 mRNA expression (TIMP-1/GAPDH mRNA, au) in saline (n = 6)- and ANG II-treated rats (n = 6). Inset: example of Northern blot showing TIMP-1 mRNA expression in both groups of rats. Data are means ± SE.

At the end of the treatment period, BW and HR were similar in the saline- and ANG II-treated groups (408.0 ± 9.4 vs. 413.0 ± 14.6 g, P = 0.78; 401.7 ± 14.1 vs. 435.7 ± 20.0 beats/min, P = 0.19, respectively).

Immunohistochemistry demonstrated no differences in TIMP-1 protein expression in aortas between saline- and ANG II-treated rats after ANG II withdrawal (Fig. 6A). Neither histological modification (Fig. 6B) nor differences in collagen content (Fig. 6C) were observed between saline- and ANG II-treated rats after ANG II withdrawal (%fibrosis: 19.1 ± 1.6 vs. 15.0 ± 2, P = 0.13).


View larger version (101K):
[in this window]
[in a new window]
  		Fig. 6.   A: representative photomicrographs (×10) of aorta immunohistochemical specimens obtained from saline- (n = 3)- and ANG II (n = 3)-treated rats 3 wk after the ANG II withdrawal. No differences are present in immunostaining for TIMP-1 antigen in aortic smooth muscle cells between saline-treated and ANG II-treated rats. B: representative histological section of aorta from saline (n = 6)- and ANG II-treated rats (n = 6). No histological changes are evident between the aortas of the two groups (hematoxylin and eosin, ×10). C: representative photomicrographs of histological aortic section of aorta used for morphometric analysis from saline (n = 6)- and ANG II-treated rats (n = 6). There are no differences in collagen content in the aortic media between the two groups (Sirius red stain, ×10).

Effects of chronic long-term ANG II infusion. Figure 7 shows the in vivo effects of chronic long-term ANG II administration on SBP, PRA, and TIMP-1 mRNA expression. As expected, after 25 days of treatment, SBP was significantly higher in the ANG II-treated rats compared with the corresponding control animals, whereas PRA in ANG II-treated animals was significantly and markedly lower than PRA of saline-treated rats. TIMP-1 mRNA expression resulted significantly higher in ANG II- than saline-treated rats.


View larger version (11K):
[in this window]
[in a new window]
  		Fig. 7.   Effects of ANG II administration for 25 days in rats. A: SBP (mmHg) *P < 0.001; B: PRA (ANG I ng · ml-1 · h-1), *P < 0.001; C: TIMP-1 mRNA expression (TIMP-1/GAPDH mRNA, au) in saline (n = 6)- and ANG II-treated rats (n = 8). Inset: example of Northern blot showing TIMP-1 mRNA expression in both rat groups. Data are means ± SE. *P < 0.05.

At the end of the treatment period, BW and HR in the saline and ANG II-treated groups were similar (391.3 ± 9.3 vs. 391.8 ± 15.3 g, P = 0.98; 417.2 ± 9.9 vs. 414.9 ± 22.8 beats/min, P = 0.93, respectively).

Immunohistochemistry demonstrated an increase in TIMP-1 protein expression in aortas of ANG II-treated rats (Fig. 8A). In ANG II-treated rats, aortic smooth muscle cells showed a stronger immunostaining of TIMP-1 than aortic smooth muscle cells of saline-treated rats. The administration of ANG II did not cause any histological modification at the vascular wall (Fig. 8B). No differences in collagen content were present between saline- and ANG II-treated rats (%fibrosis: 17.2 ± 1.3 vs. 15.0 ± 1.3, P = 0.12) (Fig. 8C).


View larger version (99K):
[in this window]
[in a new window]
  		Fig. 8.   A: representative photomicrographs (×10) of aorta immunohistochemical specimens obtained from saline (n = 4)- and ANG II (n = 4)-treated rats for 25 days. Aortic smooth muscle cells of the ANG II-treated rat show a stronger immunostaining of TIMP-1 than aortic smooth muscle cells of the saline-treated rat. B: representative histological section of aorta from saline (n = 6)- and ANG II-treated rats (n = 8). No histological changes are evident between the two groups (hematoxylin and eosin, ×10). C: representative photomicrographs of histological aortic section of aorta used for morphometric analysis from saline (n = 6)- and ANG II-treated rats (n = 8). There are no differences in collagen content (Sirius red stain, ×10) in the aortic media between the two groups of rats.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Our data demonstrate that ANG II increases TIMP-1 expression in rat aortic smooth muscle cells.

In vitro, the ANG II-induced increase in TIMP-1 mRNA expression in VSMC is time and dose dependent, and it is mediated by AT1 receptors because losartan blocks the increase in TIMP-1 expression in response to ANG II stimulation.

Repeated ANG II treatments to the cells in culture demonstrate that this increase occurs after a single stimulation but not after repeated ANG II treatments. These results may be explained by the downregulation of ANG II responsiveness to repeated applications of ANG II in VSMC. In these conditions, it has been described that ANG II downregulates its receptors, and VSMC develop an attenuation of responsiveness to ANG II through complex intracellular mechanisms implying G protein signaling pathways (24).

Our in vivo data demonstrate that short- (6 days) and long-term (25 days) chronic ANG II administrations increase TIMP-1 expression in rat aortic smooth muscle cells both at the mRNA and protein levels. The results obtained by the immunohistochemical staining demonstrate that the increase in TIMP-1 expression is mainly located in the cytoplasm of smooth muscle cells in the aorta of ANG II-treated rats. In vivo the modulation of TIMP-1 expression in the rat aorta was time related to ANG II administration. In fact, ANG II administration for 6 days induced TIMP-1 expression and this increase was evident even after a longer ANG II administration (25 days). In addition, the evidence that TIMP-1 expression was not increased after ANG II withdrawal further demonstrates the role of ANG II on TIMP-1 expression at the vascular wall.

In our experimental conditions, no differences in the medial collagen content, evaluated by morphometric analysis, were present in the aorta of ANG II-treated compared with saline-treated rats both after 6 days, as it has been described (7), and 25 days of continuous ANG II administration. These results suggest that the ANG II-dependent increase in TIMP-1 expression in the aortic smooth muscle cells occurs early, before the development of histological changes at the vascular wall.

The possibility that the increase in arterial pressure caused by chronic ANG II administration might have contributed in modulating the TIMP-1 induction cannot be excluded, although it seems unlikely because the effect of ANG II on TIMP-1 expression was first observed in VSMC in vitro, a condition in which hemodynamic and humoral influences are absent.

Increasing evidence indicates that TIMP-1 is implicated in the remodeling process leading to fibrosis (28). In spontaneously hypertensive rats, the reduced expression of TIMP-1 in the heart is associated to the regression of myocardial fibrosis (27), and recently it has also been suggested that TIMP-1 might be a potential marker of fibrosis in human hypertension (17).

ANG II plays an important role in the remodeling processes, and it contributes to atherosclerosis not only through its hemodynamic effects but also through its several proinflammatory (3, 11, 25) and profibrotic actions (14, 15). In particular, in the early phase of atherosclerosis processes, smooth muscle cells in the tunica media progressively change phenotype, losing the contractile properties and assuming the synthetic phenotype. Because TIMP-1 plays a fundamental role in tissue remodeling processes, the long-lasting ANG II induction on TIMP-1 in VSMC could contribute to the unfavorable long-term effects of ANG II at the vascular wall.

In summary, our data, by demonstrating in vivo that the increase in TIMP-1 expression induced by ANG II in VSMC occurs in absence of histological changes at the vascular wall, suggest that this effect might be involved in the early phase of the remodeling processes. It is possible to speculate that this link between ANG II and TIMP-1 in VSMC may represent a further intracellular pathway involved in the early phase of the vascular remodeling process caused by ANG II at the vascular wall level.


    ACKNOWLEDGEMENTS

The authors acknowledge Rossana Rosati for excellent histological technical assistance and Delta Sistemi (Rome, Italy) for allowing us to use the computerized imaging analysis system (IAS 2000).


    FOOTNOTES

* G. Castoldi and C. R. T. di Gioia contributed equally to this study.

Address for reprint requests and other correspondence: A. Stella, Università degli Studi di Milano-Bicocca, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Azienda Ospedaliera S. Gerardo di Monza, UDA Nefrocardiovascolare, Via Donizetti 106, 20052 Monza (MI), Italy (E-mail: andrea.stella{at}unimib.it).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

First published October 10, 2002;10.1152/ajpheart.00986.2001

Received 12 November 2001; accepted in final form 30 September 2002.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Adhikary, LP, Yamamoto T, Isome M, Nakano Y, Kawasaki K, Yaoita E, and Kihara I. Expression profile of extracellular matrix and its regulatory process of interstitial fibrosis after anti-glomerular basement membrane antibody-induced glomerular sclerosis in Sprague-Dawley rats. Pathol Int 49: 716-725, 1999[Web of Science][Medline].

2.   Brew, K, Dinakarpandian D, and Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477: 267-283, 2000[Medline].

3.   Chen, XL, Tummala PE, Olbrych MT, Alexander WR, and Medford RM. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 83: 952-959, 1998[Abstract/Free Full Text].

4.   Chesler, L, Golde DW, Bersch N, and Johnson MD. Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinase-1. Blood 86: 4506-4515, 1995[Abstract/Free Full Text].

5.   Chomczynski, P, and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987[Web of Science][Medline].

6.   Chua, CC, Hamdy RC, and Chua BH. Angiotensin II induces TIMP-1 production in rat heart endothelial cells. Biochim Biophys Acta 1311: 175-180, 1996[Medline].

7.   Diep, QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Fritsch Neves M, and Schiffrin EL. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II infused rats. Role of peroxisome proliferator-activated receptor-gamma . Circulation 105: 2296-2302, 2002[Abstract/Free Full Text].

8.   Dollery, CM, McEwan JR, and Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 77: 863-868, 1995[Free Full Text].

9.   Dzau, VJ. Tissue angiotensin and pathobiology of vascular disease. A unifying hypothesis. Hypertension 37: 1047-1052, 2001[Abstract/Free Full Text].

10.   Forough, R, Koyama N, Hasenstab D, Lea H, Clowes M, Nikkari ST, and Clowes AW. Overexpression of tissue inhibitor of metalloproteinase-1 inhibits vascular smooth muscle cell function in vitro and in vivo. Circ Res 79: 812-820, 1996[Abstract/Free Full Text].

11.   Funakoshi, Y, Ichiki T, Ito K, and Takeshita A. Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells. Hypertension 34: 118-125, 1999[Abstract/Free Full Text].

12.   Gomez, DE, Alonso DF, Yoskiji H, and Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74: 111-122, 1997[Web of Science][Medline].

13.   Guedez, L, Courtemanch L, and Stetler-Stevenson M. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood 92: 1342-1349, 1998[Abstract/Free Full Text].

14.   Hsueh, WA, Do YS, Anderson PW, and Law RE. Angiotensin II in cell growth and matrix production. Adv Exp Med Biol 377: 217-223, 1995[Medline].

15.   Kawano, H, Do YS, Kawano Y, Starnes V, Barr M, Law RE, and Hsueh WA. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 101: 1130-1137, 2000[Abstract/Free Full Text].

16.   Lin, H, Chen X, Wang J, and Yu Z. Inhibition of apoptosis in rat mesangial cells by tissue inhibitor of metalloproteinase-1. Kidney Int 62: 60-69, 2002[Web of Science][Medline].

17.   Lindsay, MM, Maxwell P, and Dunn FG. TIMP1. A marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 40: 136-141, 2002[Abstract/Free Full Text].

18.   Moreau, M, Brocheriou I, Petit L, Ninio L, Chapman MJ, and Rouis M. Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol loaded human macrophages. Relevance to stability of atherosclerotic plaque. Circulation 99: 420-426, 1999[Abstract/Free Full Text].

19.   Papakonstantinou, E, Roth M, Kokkas B, Papadopoulos C, and Karakiulakis G. Losartan inhibits the angiotensin II-induced modifications on fibrinolysis and matrix deposition by primary human vascular smooth muscle cells. J Cardiovasc Pharmacol 38: 715-728, 2001[Web of Science][Medline].

20.   Sambrook, J, Fritsch EF, and Maniatis T. Molecular Cloning (2nd ed.). Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.

21.   Shi, Y, Patel S, Niculescu R, Chung W, Desrochers P, and Zalewski A. Role of matrix metalloproteinases and their tissue inhibitors in the regulation of coronary cell migration. Arterioscler Thromb Vasc Biol 19: 1150-1155, 1999[Abstract/Free Full Text].

22.   Sperti, G, van Leeuwen RTJ, Quax PHA, Maseri A, and Kluft C. Vascular smooth muscle cells digest naturally produced extracellular matrix. Circ Res 71: 385-392, 1992[Abstract/Free Full Text].

23.   Takagishi, T, Murahashi N, Azagami S, Morimatsu M, and Sasaguri Y. Effect of angiotensin II and thromboxane A2 on the production of matrix metalloproteinase by human aortic smooth muscle cells. Biochem Mol Biol Int 35: 265-273, 1995[Web of Science][Medline].

24.   Touyz, RM, and Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 52: 639-672, 2000[Abstract/Free Full Text].

25.   Tummala, PE, Chen XL, Sundell CL, Laursen JB, Hammes P, Alexander WR, Harrison DG, and Medford RM. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature. Circulation 100: 1223-1229, 1999[Abstract/Free Full Text].

26.   Van Leeuwen, RTJ, Kol A, Andreotti F, Kluft C, Maseri A, and Sperti G. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messanger RNA in cultured aortic smooth muscle cells. Circulation 90: 362-368, 1994[Abstract/Free Full Text].

27.   Varo, N, Iraburu MJ, Varela M, Lopez B, Etayo JC, and Diez J. Chronic AT1 blockade stimulates extracellular collagen type 1 degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension 35: 1197-1202, 2000[Abstract/Free Full Text].

28.   Yoshiji, H, Kuriyama S, Miyamoto Y, Thorgeirsson UP, Gomez DE, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, Thorgeirsson SS, and Fukui H. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 32: 1248-1254, 2000[Web of Science][Medline].

Am J Physiol Heart Circ Physiol 284(2):H635-H643
0363-6135/03 $5.00 Copyright © 2003 the American Physiological Society


This article has been cited by other articles:


Home page
 Am. J. Physiol. Cell Physiol.Home page
G. E. Striker, F. Praddaude, O. Alcazar, S. W. Cousins, and M. E. Marin-Castano
Regulation of angiotensin II receptors and extracellular matrix turnover in human retinal pigment epithelium: role of angiotensin II
Am J Physiol Cell Physiol, December 1, 2008; 295(6): C1633 - C1646.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
X. Xu, W. Wan, L. Ji, S. Lao, A. S. Powers, W. Zhao, J. M. Erikson, and J. Q. Zhang
Exercise training combined with angiotensin II receptor blockade limits post-infarct ventricular remodelling in rats
Cardiovasc Res, June 1, 2008; 78(3): 523 - 532.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
S. Heeneman, J. C. Sluimer, and M. J.A.P. Daemen
Angiotensin-Converting Enzyme and Vascular Remodeling
Circ. Res., August 31, 2007; 101(5): 441 - 454.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
J. N. McDougal, C. M. Garrett, C. M. Amato, and S. J. Berberich
Effects of Brief Cutaneous JP-8 Jet Fuel Exposures on Time Course of Gene Expression in the Epidermis
Toxicol. Sci., February 1, 2007; 95(2): 495 - 510.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
E. L. Schiffrin and R. M. Touyz
From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension
Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H435 - H446.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
V. Ruiz, R. Ma. Ordonez, J. Berumen, R. Ramirez, B. Uhal, C. Becerril, A. Pardo, and M. Selman
Unbalanced collagenases/TIMP-1 expression and epithelial apoptosis in experimental lung fibrosis
Am J Physiol Lung Cell Mol Physiol, November 1, 2003; 285(5): L1026 - L1036.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
H. Ohkuma, S. Suzuki, S. Fujita, and W. Nakamura
Role of a Decreased Expression of the Local Renin-Angiotensin System in the Etiology of Cerebral Aneurysms
Circulation, August 19, 2003; 108(7): 785 - 787.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
284/2/H635    most recent
00986.2001v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (20)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Castoldi, G.
Right arrow Articles by Stella, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Castoldi, G.
Right arrow Articles by Stella, A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online